GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » YoY EPS Growth

Quantrx Biomedical (Quantrx Biomedical) YoY EPS Growth : 0.00% (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Quantrx Biomedical's YoY EPS Growth for the quarter that ended in Sep. 2022 was 0.00%.

Quantrx Biomedical's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.00.


Quantrx Biomedical YoY EPS Growth Historical Data

The historical data trend for Quantrx Biomedical's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical YoY EPS Growth Chart

Quantrx Biomedical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 200.00 -200.00 - - -

Quantrx Biomedical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 12.50 - - -

Quantrx Biomedical YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Quantrx Biomedical's YoY EPS Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EPS Growth (A: Dec. 2021 )
=(Earnings per Share (Diluted) (A: Dec. 2021 )-Earnings per Share (Diluted) (A: Dec. 2020 ))/ | Earnings per Share (Diluted) (A: Dec. 2020 ) |
=(-0.01--0.01)/ | -0.01 |
=0.00 %

Quantrx Biomedical's YoY EPS Growth for the quarter that ended in Sep. 2022 is calculated as:

YoY EPS Growth (Q: Sep. 2022 )
=(Earnings per Share (Diluted) (Q: Sep. 2022 )-Earnings per Share (Diluted) (Q: Sep. 2021 )) / | Earnings per Share (Diluted) (Q: Sep. 2021 )) |
=(-0.001--0.001)/ | -0.001 |
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantrx Biomedical YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantrx Biomedical (Quantrx Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
10190 SW 90th Avenue, Tualatin, OR, USA, 97062
Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.
Executives
Michael S Abrams director 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco director 1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk 10 percent owner 229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine director, 10 percent owner 1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr director C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton officer: V.P. of Diagnostics 209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev officer: Officer 120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman officer: Officer 5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming director, officer: Secretary
Walter W Witoshkin director, officer: President and CEO 321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc 10 percent owner 5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc 10 percent owner 570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines